胰高血糖素样肽-1受体激动剂与糖尿病视网膜病变并发症风险：来自两个国家全国登记处的队列研究 - Suppr

Glucagon-Like Peptide 1 Receptor Agonists and Risk of Diabetic Retinopathy Complications: Cohort Study in Nationwide Registers From Two Countries.

作者信息

Ueda Peter, Pasternak Björn, Eliasson Björn, Svensson Ann-Marie, Franzén Stefan, Gudbjörnsdottir Soffia, Hveem Kristian, Jonasson Christian, Melbye Mads, Svanström Henrik

机构信息

Clinical Epidemiology Division, Department of Medicine, Solna, Karolinska Institutet, Stockholm, Sweden

Clinical Epidemiology Division, Department of Medicine, Solna, Karolinska Institutet, Stockholm, Sweden.

出版信息

Diabetes Care. 2019 Jun;42(6):e92-e94. doi: 10.2337/dc18-2532. Epub 2019 Apr 22.

DOI:10.2337/dc18-2532

PMID:31010872

Abstract

摘要

相似文献

Glucagon-Like Peptide 1 Receptor Agonists and Risk of Diabetic Retinopathy Complications: Cohort Study in Nationwide Registers From Two Countries.胰高血糖素样肽-1受体激动剂与糖尿病视网膜病变并发症风险：来自两个国家全国登记处的队列研究

Diabetes Care. 2019 Jun;42(6):e92-e94. doi: 10.2337/dc18-2532. Epub 2019 Apr 22.

The potential benefits of glucagon-like peptide-1 receptor agonists for diabetic retinopathy.胰高血糖素样肽-1 受体激动剂治疗糖尿病视网膜病变的潜在益处。

Peptides. 2018 Feb;100:123-126. doi: 10.1016/j.peptides.2017.08.003. Epub 2017 Aug 12.

Glucagon-Like Peptide 1 Receptor Agonists and the Risk of Incident Diabetic Retinopathy.胰高血糖素样肽-1 受体激动剂与新发糖尿病视网膜病变风险。

Diabetes Care. 2018 Nov;41(11):2330-2338. doi: 10.2337/dc17-2280. Epub 2018 Aug 27.

Efficacy and safety of glucagon-like peptide-1 agonists on macrovascular and microvascular events in type 2 diabetes mellitus: A meta-analysis.胰高血糖素样肽-1激动剂对2型糖尿病大血管和微血管事件的疗效及安全性：一项荟萃分析。

Nutr Metab Cardiovasc Dis. 2017 Dec;27(12):1081-1088. doi: 10.1016/j.numecd.2017.09.006. Epub 2017 Sep 28.

Pleiotropic effects of glucagon-like peptide-1 (GLP-1)-based therapies on vascular complications in diabetes.胰高血糖素样肽-1（GLP-1）类药物治疗对糖尿病血管并发症的多效作用。

Curr Pharm Des. 2011 Dec;17(38):4379-85. doi: 10.2174/138161211798999456.

No pancreatic safety concern following glucagon-like peptide-1 receptor agonist therapies: A pooled analysis of cardiovascular outcome trials.GLP-1 受体激动剂治疗后无胰腺安全性担忧：心血管结局试验的汇总分析。

Diabetes Metab Res Rev. 2018 Nov;34(8):e3061. doi: 10.1002/dmrr.3061. Epub 2018 Sep 14.

Glucagon-like peptide 1 receptor agonists and cardiovascular risk in type 2 diabetes: a clinical perspective.胰高血糖素样肽 1 受体激动剂与 2 型糖尿病患者的心血管风险：临床视角。

Diabetes Obes Metab. 2015 Apr;17(4):335-42. doi: 10.1111/dom.12380. Epub 2014 Sep 17.

The Effect of Glucagon-Like Peptide 1 Receptor Agonists on Weight Loss in Type 2 Diabetes: A Systematic Review and Mixed Treatment Comparison Meta-Analysis.胰高血糖素样肽-1受体激动剂对2型糖尿病患者体重减轻的影响：一项系统评价与混合治疗比较的Meta分析

PLoS One. 2015 Jun 29;10(6):e0126769. doi: 10.1371/journal.pone.0126769. eCollection 2015.

[Impact of anti-diabetic therapy based on glucagon-like peptide-1 receptor agonists on the cardiovascular risk of patients with type 2 diabetes mellitus].基于胰高血糖素样肽-1受体激动剂的抗糖尿病治疗对2型糖尿病患者心血管风险的影响

Med Clin (Barc). 2013 Aug 17;141(4):167-74. doi: 10.1016/j.medcli.2012.11.016. Epub 2013 Jan 18.

Microvascular effects of glucagon-like peptide-1 receptor agonists in type 2 diabetes: a meta-analysis of randomized controlled trials.胰高血糖素样肽-1 受体激动剂在 2 型糖尿病中的微血管作用：一项随机对照试验的荟萃分析。

Acta Diabetol. 2017 Oct;54(10):933-941. doi: 10.1007/s00592-017-1031-9. Epub 2017 Jul 27.

引用本文的文献

Impact of GLP-1 Agonists and SGLT-2 Inhibitors on Diabetic Retinopathy Progression: An Aggregated Electronic Health Record Data Study.GLP-1 激动剂和 SGLT-2 抑制剂对糖尿病视网膜病变进展的影响：一项汇总电子健康记录数据研究。

Am J Ophthalmol. 2024 Sep;265:39-47. doi: 10.1016/j.ajo.2024.04.010. Epub 2024 Apr 17.

Novel Antidiabetic Drugs and the Risk of Diabetic Retinopathy: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.新型抗糖尿病药物与糖尿病视网膜病变风险：随机对照试验的系统评价和荟萃分析

J Clin Med. 2024 Mar 20;13(6):1797. doi: 10.3390/jcm13061797.

The incidence of retinopathy in the Glycemia Reduction Approaches in Diabetes: A Comparative Effectiveness study (GRADE).糖尿病血糖控制治疗的比较效果研究（GRADE）中的视网膜病变发生率。

J Diabetes Complications. 2024 Mar;38(3):108692. doi: 10.1016/j.jdiacomp.2024.108692. Epub 2024 Feb 5.

Glucagon-Like Peptide-1 Receptor Agonist and Risk of Diabetic Retinopathy in Patients with Type 2 Diabetes Mellitus: A Systematic Review and Meta-analysis of Randomized Placebo-Controlled Trials.胰高血糖素样肽-1受体激动剂与2型糖尿病患者糖尿病视网膜病变风险：一项对随机安慰剂对照试验的系统评价和荟萃分析

Clin Drug Investig. 2023 Dec;43(12):915-926. doi: 10.1007/s40261-023-01319-x. Epub 2023 Nov 8.

Semaglutide-eye-catching results.司美格鲁肽——引人注目的结果。

World J Diabetes. 2023 Apr 15;14(4):424-434. doi: 10.4239/wjd.v14.i4.424.

Glucagon-like peptide-1 receptor agonists and diabetic retinopathy: nationwide cohort and Mendelian randomization studies.胰高血糖素样肽-1 受体激动剂与糖尿病视网膜病变：全国性队列研究和孟德尔随机化研究。

BMC Med. 2023 Feb 3;21(1):40. doi: 10.1186/s12916-023-02753-6.

Semaglutide and Diabetic Retinopathy Risk in Patients with Type 2 Diabetes Mellitus: A Meta-Analysis of Randomized Controlled Trials.司美格鲁肽与 2 型糖尿病患者糖尿病视网膜病变风险：一项随机对照试验的荟萃分析。

Clin Drug Investig. 2022 Jan;42(1):17-28. doi: 10.1007/s40261-021-01110-w. Epub 2021 Dec 11.

Profiles of Intraday Glucose in Type 2 Diabetes and Their Association with Complications: An Analysis of Continuous Glucose Monitoring Data.2 型糖尿病患者日内血糖特征及其与并发症的关系：连续血糖监测数据分析。

Diabetes Technol Ther. 2021 Aug;23(8):555-564. doi: 10.1089/dia.2020.0672. Epub 2021 May 11.

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Glucagon-Like Peptide 1 Receptor Agonists and Risk of Diabetic Retinopathy Complications: Cohort Study in Nationwide Registers From Two Countries.

作者信息

机构信息

出版信息

相似文献

引用本文的文献

文献检索

文件翻译

深度研究

Suppr 超能文献

相似文献

引用本文的文献